Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Initiatives
ABT logo

Abbott Bets $23 Billion on Cancer Diagnostics Amid 12% Medical Device Growth

ABT10-KFiling Date: 2/20/2026
Abbott Laboratories
Description

What this story covers

Abbott Laboratories is pivoting toward high-growth medical devices and cancer diagnostics, highlighted by a pending $23 billion acquisition of Exact Sciences. While facing significant legal challenges regarding infant formula, strong cash flows and device innovation drive its global strategy.

Story snapshot

CompanyAbbott Laboratories
TickerABT
VariantStandard detailed
Duration12:45
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001628280-26-010185
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in